ChemPartner PharmaTech Co Ltd Asset Resilience Ratio
ChemPartner PharmaTech Co Ltd asset resilience ratio. ChemPartner PharmaTech Co Ltd (300149) has an Asset Resilience Ratio of 1.67% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read ChemPartner PharmaTech Co Ltd total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of ChemPartner PharmaTech Co Ltd (2014–2025)
Asset resilience ratio of ChemPartner PharmaTech Co Ltd from 2014 to 2025. This chart shows how ChemPartner PharmaTech Co Ltd's Asset Resilience Ratio has changed over time. See 300149 FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Liquid Assets Composition Over Time
This chart breaks down ChemPartner PharmaTech Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see balance sheet size of ChemPartner PharmaTech Co Ltd.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥33.99 Million | 1.67% |
| Total Liquid Assets | CN¥33.99 Million | 1.67% |
Asset Resilience Insights
- Limited Liquidity: ChemPartner PharmaTech Co Ltd maintains only 1.67% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
ChemPartner PharmaTech Co Ltd Industry Peers by Asset Resilience Ratio
Compare ChemPartner PharmaTech Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
CSL Ltd
AU:CSL |
Biotechnology | 0.41% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND |
Biotechnology | 16.06% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076 |
Biotechnology | 0.91% |
|
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX |
Biotechnology | 78.22% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
|
PHARMING GRP SP. ADRS
F:PHG |
Biotechnology | 6.76% |
ChemPartner PharmaTech Co Ltd Asset Resilience Ratio by Year (2014–2025)
ChemPartner PharmaTech Co Ltd asset resilience ratio by year from 2014 to 2025. The table below shows the annual Asset Resilience Ratio data for ChemPartner PharmaTech Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 2.24% | CN¥45.57 Million ≈ $6.67 Million |
CN¥2.03 Billion ≈ $297.48 Million |
+2.19pp |
| 2024-12-31 | 0.05% | CN¥1.05 Million ≈ $153.04K |
CN¥2.00 Billion ≈ $292.05 Million |
-0.04pp |
| 2023-12-31 | 0.09% | CN¥2.21 Million ≈ $322.75K |
CN¥2.43 Billion ≈ $356.22 Million |
-0.36pp |
| 2021-12-31 | 0.45% | CN¥18.98 Million ≈ $2.78 Million |
CN¥4.22 Billion ≈ $617.17 Million |
-0.04pp |
| 2020-12-31 | 0.49% | CN¥20.08 Million ≈ $2.94 Million |
CN¥4.12 Billion ≈ $603.12 Million |
-1.22pp |
| 2019-12-31 | 1.71% | CN¥64.40 Million ≈ $9.42 Million |
CN¥3.77 Billion ≈ $551.34 Million |
-10.21pp |
| 2017-12-31 | 11.92% | CN¥124.34 Million ≈ $18.19 Million |
CN¥1.04 Billion ≈ $152.65 Million |
-27.54pp |
| 2016-12-31 | 39.46% | CN¥313.00 Million ≈ $45.80 Million |
CN¥793.16 Million ≈ $116.06 Million |
-3.92pp |
| 2015-12-31 | 43.39% | CN¥328.00 Million ≈ $48.00 Million |
CN¥756.00 Million ≈ $110.63 Million |
+38.26pp |
| 2014-12-31 | 5.13% | CN¥38.00 Million ≈ $5.56 Million |
CN¥741.13 Million ≈ $108.45 Million |
-- |
About ChemPartner PharmaTech Co Ltd
ChemPartner PharmaTech Co.,Ltd. engages in the microecological nutrition and healthcare businesses worldwide. The company operates in two segments, Microecological Nutrition and Medical Business; and Pharmaceutical Research and Development Service and Production Outsourcing Business. It offers prebiotic products and the provision of microecological medical services. The company provides comprehen… Read more